Physiologically Based Pharmacokinetic Modeling of Vedolizumab in Healthy Adults and Patients with Inflammatory Bowel Disease

Sanjana Parikh, Kei Irie, Ryota Tanaka, Takanobu Nadai, Phillip Minar, Tomoyuki Mizuno · 2026

Read Physiologically Based Pharmacokinetic Modeling of Vedolizumab in Healthy Adults and Patients with Inflammatory Bowel Disease by Sanjana Parikh, Kei Irie, Ryota Tanaka, Takanobu Nadai, Phillip Minar, Tomoyuki Mizuno (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13545043.txt.

Description

Sanjana Parikh and colleagues published a 2026 modelling study of vedolizumab, a gut-selective antibody drug for ulcerative colitis and Crohn's disease, asking how inflammation severity changes the drug's path through the body. Exposure varies with disease activity because the drug is consumed by binding its target. Their physiologically based model, built in a standard simulation platform, included that target-mediated disposal and was first checked against healthy-volunteer data.

The model reproduced observed blood levels closely across a wide dose range in healthy adults, with predicted-to-observed ratios mostly between eight- and eleven-tenths. For patients, the team let the amount of target rise with inflammation, as the biology dictates, and predictions for mild-to-moderate colitis again landed near the observed values. A verified model of this kind can forecast dosing in sicker patients before trials enrol them, the authors argue.

Catalog record

CREATORSanjana Parikh, Kei Irie, Ryota Tanaka, Takanobu Nadai, Phillip Minar, Tomoyuki Mizuno
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE36 KB
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13545043

Browse the full library · About the Tower of Babel